BLING III: A phase III randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients

这项由澳大利亚主导的具有全球意义的试验将为使用β-内酰胺类抗生素治疗严重脓毒症患者的最佳方法提供明确的临床证据。该试验将比较连续输注β-内酰胺类抗生素与标准间歇给药相比是否能改善患者的结局。这项试验的潜在意义在于，它可能导致一种简单且具有成本效益的干预措施，以改善严重感染患者的生存率。

This Australian-led trial of global significance will provide definitive clinical evidence of the optimal method for treating patients with severe sepsis using beta-lactam antibiotics. The trial will compare whether continuous infusion of beta-lactam antibiotics improves outcomes for patients compared with standard intermittent dosing. The potential significance of this trial is that it may lead to a simple and cost-effective intervention to improve survival for patients with severe infections.